Mayne Pharma (ASX:MYX) has agreed to a $604 million takeover by Hungarian pharmaceutical company Gedeon Richter, with shareholders being offered $6.40 per share in cash under a proposed scheme of arrangement.
The proposed acquisition represents a 99.4% premium to Mayne Pharma’s closing share price on November 16, 2026, offering investors a significant opportunity to realise value from their holdings.
Under the agreement, Richter will acquire 100% of Mayne Pharma through an Australian nominee company, with the transaction valuing the company’s equity at approximately $604 million.
The offer also represents premiums of 124%, 122% and 145% to Mayne Pharma’s 30-day, 90-day and 180-day volume-weighted average share prices respectively.
Mayne Pharma’s board has unanimously recommended shareholders vote in favour of the scheme, in the absence of a superior proposal and subject to an independent expert concluding that the deal is in shareholders’ best interests.
The company’s three largest shareholders, collectively holding 22.14% of shares on issue, have also indicated their intention to vote in favour of the transaction.
The acquisition is expected to provide Richter with an opportunity to expand its international pharmaceutical operations, particularly across women’s healthcare and dermatology.
Mayne Pharma’s US women’s health and dermatology/DistributeRx franchises were identified as key strengths underpinning the transaction.
Richter, headquartered in Budapest, Hungary, operates across women’s healthcare, neuropsychiatry, biotechnology and general medicines. Its women’s healthcare division generated €826 million in sales during FY25.
What’s next?
The proposed takeover remains subject to several conditions, including Foreign Investment Review Board approval, US antitrust clearance, shareholder approval and court approval.
Completion of Mayne Pharma’s previously announced $55.5 million sale of its International business to Evaris Pharma is also a condition of the scheme.
A shareholder meeting is expected in late January 2027, with implementation anticipated in mid-to-late March 2027, subject to the required approvals.
Mayne Pharma shareholders do not need to take any action at this stage, with further information expected through a scheme booklet ahead of the shareholder meeting.
Join the discussion: See what HotCopper users are saying about Mayne Pharma Group and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please clickhere.
